Adding vitamin E-TPGS to the formulation of Genexol-PM: specially mixed micelles improve drug-loading ability and cytotoxicity against multidrug-resistant tumors significantly.
Zhuoyang Fan, Cheng Chen, Xiaoying Pang, Zhou Yu, Yang Qi, Xinyi Chen, Huihui Liang, Xiaoling Fang, Xianyi Sha
Index: PLoS ONE 10(4) , e0120129, (2015)
Full Text: HTML
Abstract
Genexol-PM, produced by Samyang Company (Korea) is an excellent preparation of paclitaxel (PTX) for clinical cancer treatment. However, it cannot resolve the issue of multidrug resistance (MDR)-a significant problem in the administration of PTX to cancer patients. To increase the efficacy of Genexol-PM against MDR tumors, a mixed micelle capable of serving as a vehicle for PTX was developed, and two substances were chosen as carrier materials: 1) Polyethylene glycol-polylactic acid (PEG-PLA), the original vehicle of Genexol-PM. 2) Vitamin E-TPGS, an inhibitor of P-glycoprotein (P-gp). P-gp has been proven to be the main cause of MDR. In vitro evaluation indicated that the mixed micelle was an ideal PTX delivery system for the treatment of MDR tumors; the mixed micelle also showed a significantly better drug-loading coefficient than Genexol-PM.
Related Compounds
Related Articles:
2015-01-15
[J. Ethnopharmacol. 159 , 93-101, (2014)]
2014-11-01
[J. Am. Soc. Mass Spectrom. 25(11) , 1897-907, (2014)]
2014-07-01
[Autophagy 10(7) , 1241-55, (2014)]
2015-01-01
[Arch. Toxicol. 89(1) , 107-19, (2015)]
2014-12-01
[Biochim. Biophys. Acta 1842(12 Pt A) , 2345-56, (2014)]